Xylooligosaccharides attenuates insulin resistance in obese mice by modification of short-chain fatty acids
Abdullah Abdulaziz Abbod Abdo, Chengnan Zhang, Xiuting Li
Diabetes is a major public health concern worldwide. In our previous study, we reported that XOS supplementations for 12 weeks could successfully attenuated obesity, improved glucose intolerance and fasting blood glucose in mice fed a high fat diet. However, how dietary XOS improved blood glucose remains vague. Therefore, this study was designed to examine the effect of dietary XOS supplementation on insulin resistance in obese mice. Levels of fasting insulin were measured in the blood of mice fed one of the following diets: low-fat diet (LFD), high-fat diet (HFD), HFD plus 5 XOS (LXD) and HFD plus 10 % XOS (HXD). Levels of blood Ghcagons-like peptide 1 (GLP-1) and hepatic Free fatty acids (FFAs) were determined by Mouse ELISA Kit and GC respectively, insulin sensitivity was evaluated by using HOMA2 and QUICKI indexes, and Short-chain fatty acids (SCFAs) in fecal of mice were measured by HPLC. Compared to the HFD group, the LXD and HXD groups displayed a remarkable attenuation in insulin resistance. This attenuation was accompanied with an increase in levels of the hormone of GLP-1 as well as the production of acetate, propionate, butyrate, and total SCFAs. By contrast, long-chain FFAs in the liver including saturated fatty acids (SFAs), Monounsaturated fatty acids (MUFAs), polyunsaturated fatty acids (PUFAs), and total FFAs were reduced by XOS supplementations. These results suggest that feeding of XOS can efficiently suppress insulin resistance in the HFD-induced obese mice by enhancing SCFAs production.